[Gene therapy for myeloid leukemia].
Among several immune-gene therapies against myeloid leukemia, "T cell depleted haplo-identical transplantation with HSV-TK gene modified T cell add-back" and "donor lymphocyte infusion using HSV-TK gene modified T cell in patients experiencing recurrence after allogeneic stem cell transplantation" were in advanced stages of clinical development. In this chapter, I will summarize the strategies of gene therapy using HSV-TK gene modified T lymphocyte in allogeneic stem cell transplantation. I will also point out the current situation of other gene therapies such as cytokine gene modified CML-DC and TCR gene modified T lymphocyte against myeloid leukemia.
Heike
Yuji
Y
Department of Medical Oncology, National Cancer Center Hospital.
D018952:Antigens, CD34; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007951:Leukemia, Myeloid / Q000628:therapy*; D017710:Lymphocyte Transfusion; D018139:Simplexvirus / Q000201:enzymology*; D033581:Stem Cell Transplantation; D013601:T-Lymphocytes / Q000637:transplantation*; D013937:Thymidine Kinase / Q000235:genetics*
D018952:Antigens, CD34; D013937:Thymidine Kinase